|
Price : 5 slide for 600 $
| CSN1 Human, non-neoplastic liver | |||||
| Age | Sex | Diagnosis | Patients' major problem | No. of CS1# | |
| 101 | 68 | M | reactive hepatitis | rectum adenocarcinoma | |
| 102 | 60 | M | reactive hepatitis | rectum adenocarcinoma | |
| 103 | 63 | F | nonspecific reactive change | colon adenocarcinoma | |
| 104 | 57 | M | chronic persistent hepatitis | HCC | 2 |
| 105 | 47 | M | nonspecific reactive change | rectum adenocarcinoma | |
| 106 | 50 | M | reactive hepatitis | stomach adenocarcinoma | |
| 107 | 65 | F | nonspecific reactive change | colon adenocarcinoma | |
| 108 | 43 | F | reactive hepatitis | gallbladder cancer | |
| 109 | 48 | M | reactive hepatitis with steatosis | gallbladder cancer | |
| 110 | 67 | M | reactive hepatitis | colon adenocarcinoma | |
| 111 | 59 | M | reactive hepatitis | colon adenocarcinoma | |
| 112 | 52 | M | chronic active hepatitis | HCC | 7 |
| 113 | 60 | M | reactive hepatitis | gallbladder cancer | |
| 114 | 52 | F | reactive hepatitis | gallbladder cancer | |
| 115 | 58 | M | reactive hepatitis with cholestasis | common bile duct carcinoma | |
| 116 | 48 | F | reactive hepatitis | stomach adenocarcinoma | |
| 117 | 62 | F | nonspecific reactive change | colon adenocarcinoma | |
| 118 | 52 | M | nonspecific reactive change | colon adenocarcinoma | |
| 119 | 73 | F | reactive hepatitis with cholestasis | gallbladder cancer | |
| 120 | 30 | M | reactive hepatitis with cholestasis | common bile duct cancer | |
| 121 | 45 | M | chronic active hepatitis | colon adenocarcinoma | |
| 122 | 71 | M | reactive hepatitis | rectum adenocarcinoma | |
| 123 | 61 | M | reactive hepatitis | stomach adenocarcinoma | |
| 124 | 71 | M | nonspecific reactive change | lung adenocarcinoma | |
| 125 | 59 | M | nonspecific reactive change | colon adenocarcinoma | |
| 126 | 67 | M | reactive hepatitis | cholangiocarcinoma | |
| 127 | 62 | M | nonspecific reactive change | colon adenocarcinoma | |
| 128 | 52 | M | nonspecific reactive change with steatosis | rectum adenocarcinoma | |
| 129 | 74 | F | nonspecific reactive change with steatosis | colon adenocarcinoma | |
| 130 | 81 | M | nonspecific reactive change | common bile duct cancer | |
| 131 | 37 | M | chronic persistent hepatitis | HCC | 14 |
| 132 | 75 | M | macronodular cirrhosis | HCC | 15 |
| 133 | 32 | M | macro- and micronodular cihhrosis | combined HCC & cholangiocarcinoma | 17 |
| 134 | 57 | M | micronodular cirrhosis | HCC | 19 |
| 135 | 65 | M | chronic persistent hepatitis | HCC | 22 |
| 136 | 52 | M | macro- and micronodular cihhrosis | HCC | 23 |
| 137 | 65 | M | macronodular cirrhosis | HCC | 24 |
| 138 | 72 | M | reactive hepatitis | HCC | 25 |
| 139 | 58 | F | macro- and micronodular cihhrosis | HCC | 26 |
| 140 | 52 | M | micronodular cirrhosis | HCC | 27 |
| 141 | 40 | M | macro- and micronodular cihhrosis | HCC | 28 |
| 142 | 53 | F | macro- and micronodular cihhrosis | HCC | 29 |
| 143 | 67 | M | macro- and micronodular cihhrosis | HCC | 30 |
| 144 | 47 | M | reactive hepatitis | HCC | 34 |
| 145 | 65 | M | dysplastic nodule, high grade | HCC | 37 |
| 146 | 63 | F | macro- and micronodular cihhrosis | HCC | 38 |
| 147 | 60 | F | macronodular cirrhosis | HCC | 39 |
| 148 | 65 | F | macronodular cirrhosis | HCC | 40 |
| 149 | 66 | F | micronodular cirrhosis | HCC | 42 |
| 150 | 65 | F | macronodular cirrhosis | HCC | 43 |
| 151 | 64 | M | macro- and micronodular cihhrosis | HCC | 46 |
| 152 | 51 | M | macro- and micronodular cihhrosis | HCC | 47 |
| 153 | 65 | F | macro- and micronodular cihhrosis | HCC | 48 |
| 154 | 51 | M | chronic persistent hepatitis | HCC | 52 |
| 155 | 49 | M | chronic persistent hepatitis | HCC | 53 |
| 156 | 57 | F | chronic persistent hepatitis | HCC | 54 |
| 157 | 57 | M | reactive hepatitis | HCC | 55 |
| 158 | 50 | M | reactive hepatitis | HCC | 57 |
| 159 | 43 | M | micronodular cirrhosis | HCC | 58 |
| 160 | carbon | ||||
| HCC : hepatocellular carcinoma | |||||
| #: Cancer tissue in CS1 of corresponding number is from the identical patient. | |||||
General Information of the Tissue Array Slide :
Applications
- Immunohistochemistry
- In situ hybridization, RNA or DNA
- Fluorescent in situ hybridization (FISH)
- In situ PCR, RNA or DNA
- TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)
Storage and stability
- Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
- Tissue array slides are shipped in room temperature.
- If the slides are stored in 4 degree, they are good up to one year.
How processed
- Tissues were initially fixed with formalin except for some of the animal tissues.
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)
Before use
- Dry slides for 1 hour in a oven at 60 degree.
- Dewax slides in xylene for 4 minutes x 5 times
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes
Slide orientation
- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.
|
Shaded area |
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
| 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
| 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 |